Achilles Therapeutics Plc to Post Q1 2023 Earnings of ($0.49) Per Share, Oppenheimer Forecasts (NASDAQ:ACHL)
Achilles Therapeutics Plc to Post Q1 2023 Earnings of ($0.49) Per Share, Oppenheimer Forecasts (NASDAQ:ACHL)
Achilles Therapeutics plc (NASDAQ:ACHL – Get Rating) – Analysts at Oppenheimer reduced their Q1 2023 earnings per share estimates for Achilles Therapeutics in a report released on Tuesday, March 7th. Oppenheimer analyst M. Breidenbach now anticipates that the company will post earnings of ($0.49) per share for the quarter, down from their prior estimate of ($0.38). Oppenheimer has a "Market Perform" rating on the stock. The consensus estimate for Achilles Therapeutics' current full-year earnings is ($1.66) per share. Oppenheimer also issued estimates for Achilles Therapeutics' Q2 2023 earnings at ($0.49) EPS, Q3 2023 earnings at ($0.49) EPS, Q4 2023 earnings at ($0.50) EPS, FY2023 earnings at ($1.96) EPS, FY2024 earnings at ($1.55) EPS, FY2025 earnings at ($1.72) EPS and FY2026 earnings at ($1.85) EPS.
阿喀琉斯治療有限公司（NASDAQ：ACHL — 獲得評級）— 奧本海默的分析師在 3 月 7 日（星期二）發布的一份報告中，降低了阿喀琉斯治療的 2023 年第一季度每股收入估計。奧本海默分析師布雷登巴赫現在預計，該公司將公布本季度每股收益（0.49 美元），低於其先前的估計（0.38 美元）。奧本海默對股票有「市場表現」評級。阿喀琉斯治療目前全年收益的共識估計為每股（1.66 美元）。奧本海默還發布了阿基里斯治療第二季盈利 2023 年第二季盈利（0.49 美元）、2023 年第三季盈利為每股盈利（0.49 美元）、每股收益 0.50 美元、FY2024 盈利為每股盈利（1.55 美元）、FY2025 盈利在每股盈利（1.72 美元）和 FY2026 盈利（1.85 美元）。FY2023
ACHL has been the subject of a number of other reports. Piper Sandler cut their target price on Achilles Therapeutics from $10.00 to $8.00 and set an "overweight" rating for the company in a research note on Tuesday, December 6th. Chardan Capital lowered their target price on Achilles Therapeutics from $17.00 to $12.00 in a report on Wednesday.
ACHL 一直是許多其他報告的主題。派珀·桑德勒（Piper Sandler）將跟腱治療的目標價格從 10.00 美元降至 8.00 美元，並在 12 月 6 日（星期二）的一份研究報告中為該公司設定了「超重」評級。查丹資本週三的一份報告中，將阿喀琉斯治療的目標價格從 17.00 美元降至 12.00 美元。
Achilles Therapeutics Stock Down 4.5 %
阿喀琉斯治療股票下降 4.5%
Shares of NASDAQ ACHL opened at $0.95 on Friday. The stock has a market cap of $37.19 million, a PE ratio of -0.52 and a beta of 0.98. The company has a quick ratio of 10.43, a current ratio of 10.93 and a debt-to-equity ratio of 0.02. Achilles Therapeutics has a 52-week low of $0.75 and a 52-week high of $3.45. The business has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.73.
納斯達克 ACHL 的股票上週五以 0.95 美元開盤。該股的市值為 37.19 萬美元，私募股票比率為 -0.52，貝塔值為 0.98。該公司的快速比率為 10.43，流動比率為 10.93，債務與權益比率為 0.02。跟腱治療有 52 週的低點 0.75 美元和 52 周的高點 3.45 美元。該業務的 50 天移動平均價格為 1.14 美元，200 日移動平均價格為 1.73 美元。
Institutional Trading of Achilles Therapeutics
阿喀琉斯治療的機構交易
Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC boosted its stake in Achilles Therapeutics by 498.2% in the fourth quarter. Renaissance Technologies LLC now owns 484,733 shares of the company's stock valued at $436,000 after acquiring an additional 403,700 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Achilles Therapeutics by 18.6% in the third quarter. Point72 Asset Management L.P. now owns 2,107,595 shares of the company's stock valued at $4,763,000 after buying an additional 330,851 shares in the last quarter. Kettle Hill Capital Management LLC bought a new position in shares of Achilles Therapeutics in the second quarter valued at $612,000. Millennium Management LLC bought a new position in shares of Achilles Therapeutics in the fourth quarter valued at $74,000. Finally, BlackRock Inc. grew its position in Achilles Therapeutics by 25.5% during the 1st quarter. BlackRock Inc. now owns 266,657 shares of the company's stock worth $784,000 after purchasing an additional 54,225 shares in the last quarter. 69.66% of the stock is owned by hedge funds and other institutional investors.
對沖基金和其他機構投資者最近修改了其業務的持有情況。文藝復興技術有限責任公司在第四季度將其在阿喀琉斯治療的股份提高了 498.2％。文藝復興科技有限責任公司現在擁有該公司的 484,733 股股份，價值為 436,000 美元，在此期間額外收購 403,700 股股票後。72 點資產管理有限責任公司在第三季度增加了其在阿喀琉斯治療的股份持有量 18.6%。在上一季度額外購買 330,851 股股份後，Point72 資產管理有限責任公司股票的 2,107,595 股價值為 4,763,000 美元，現在擁有該公司股票的 2,107,595 股股份。水壺山資本管理有限責任公司在第二季度買了阿喀琉斯治療學股份的新位置，價值 612,000 美元。千禧管理有限責任公司在第四季度購買了阿喀琉斯治療學股份的新位置，價值為 74,000 美元。最後，貝萊德公司在第一季度將其在阿基里斯治療領域的地位增長了 25.5％。在上一季度額外購買 54,225 股股票後，貝萊德公司現在擁有該公司股票 266,657 股價值 784,000 美元。69.66％ 的股票由對沖基金和其他機構投資者擁有。
About Achilles Therapeutics
關於阿喀琉斯治療
(Get Rating)
(取得評分)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.
Achilles Theraptics Plc 是一家臨床階段免疫腫瘤生物製藥公司，致力於開發精密 T 細胞療法，用於治療各種實體瘤。該公司的主要候選產品包括 CHIRON，該試驗處於用於治療晚期非小細胞肺癌的 I/Ia 期臨床試驗；以及用於治療轉移性或復發性黑色素瘤的 I/Ia 期臨床試驗中的候選產品 THETIS。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Achilles Therapeutics (ACHL)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
- 獲取有關阿喀琉斯治療學（ACHL）的研究報告的免費副本
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
- 甲骨文已經說話:股價下跌 5%
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收阿喀琉斯治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關阿喀琉斯治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。